Common adverse reactions The most common adverse reactions (≥20% of patients) listed in the prescribing information include:1 Corneal epithelium change on eye exam (keratopathy) Decreased visual acuity Nausea Blurred vision Increased body temperature (pyrexia) Infusion-related reactions Fatigue Serious adverse reactions The serious adverse reactions listed in the prescribing information include:1 Decreased platelets Decreased lymphocytes Decreased hemoglobin Decreased neutrophils Increased creatinine Increased gamma-glutamyl transferase Use in a specific population Blenrep (belantamab mafodotin-blmf) can cause fetal harm when administered to a pregnant woman; it is advised to avoid pregnancies and breastfeeding.1 For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.1 References 1. Full prescribing information [FDA]: Blenrep (belantamab mafodotin-blmf) [PDF] GlaxoSmithKline, August 6, 2020 2. Targeting the Microtubular Network as a New Antimyeloma Strategy Feng R, Molecular Cancer Therapeutics, Oct 2011 3. What Is Multiple Myeloma